search
Back to results

Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa (coArtHA)

Primary Purpose

Arterial Hypertension

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
dual combination
triple combination
Standard of care
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Arterial Hypertension focused on measuring antihypertensive treatment

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • HIV-positive and negative patients of African descent and black ethnicity with a documented uncomplicated, untreated arterial hypertension (blood pressure >/=140/90 mmHg) diagnosed at one of the 2 study sites

Exclusion Criteria:

  • Current hospitalization for any reason
  • Not of African descent
  • Refusal of an HIV-test or indeterminate HIV test result
  • History of cardiovascular event in the last month (anginal pain, stroke, myocardial infarction or diagnosis by a doctor)
  • Symptomatic arterial hypertension (blood pressure >/=180/110 mmHg plus headache or chest pain) or acute cardiovascular event
  • acute disease, (e.g. fever >37.5°C or other signs of acute concomitant infection; Dyspnea/respiratory distress; Acute pain)
  • Clinical signs of hypertension-mediated organ damage (heart failure, bilateral pitting edema, bilateral crackles or pleural effusion, distended jugular veins, ischemic heart disease (anginal pain on exertion), signs of current ischemic/hemorrhagic stroke (hemiparesis, loss of consciousness)
  • Pregnancy (test required for females 18-45years of age)
  • Non-consenting or inability to come for follow-up visits
  • creatinine clearance </=30ml/min by Chronic Kidney Disease Epidemiology Formula (CK-EPI) estimation and measurement with a point-of care creatinine from capillary blood

Sites / Locations

  • SolidarMed Lesotho, Mokhotlong Government Hospital
  • Division of Infectious Diseases & Hospital Epidemiology; University Hospital Basel
  • St. Francis Referral Hospital/ Ifakara Health Institute

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Intervention 1: dual combination

Intervention 2: triple combination

Standard of care

Arm Description

dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point

triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point

start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point

Outcomes

Primary Outcome Measures

Proportion of patients reaching a target blood pressure
Proportion of patients reaching a target blood pressure (clinic blood pressure) of </=130/80 mmHg in patients <65years of age and </=140/90 mmHg in patients >65years of age

Secondary Outcome Measures

Proportion of patients reaching a target blood pressure
Proportion of patients reaching a target blood pressure (clinic blood pressure) of </=130/80mmHg in patients <65years of age and </=140/90mmHg in patients >65years of age
Change in blood pressure (mmHg)
Change in blood pressure (change from enrolment) (mmHg)
Proportion of patients with treatment adaptations made to the primary treatment
Proportion of patients with treatment adaptations made to the primary treatment (dose increases and/or drug additions)
Number of treatment adaptations per patient made to the primary treatment
Number of treatment adaptations per patient made to the primary treatment
Time until first target blood pressure of </=130/80 mmHg in patients <65years of age and </=140/90mmHg in patients >65years of age
Time until first target blood pressure of </=130/80 mmHg in patients <65years of age and </=140/90mmHg in patients >65years of age
Proportion of patients with major cardiovascular endpoints
Proportion of patients with major cardiovascular endpoints such as death, stroke, myocardial infarction, heart failure)
Proportion of patients with changes in surrogate markers for hypertension-mediated organ damage
Proportion of patients with changes in surrogate markers for hypertension-mediated organ damage (resolving, newly occurring or worsening)
Proportion of patients lost to follow up or stopped treatment
Proportion of patients lost to follow up or stopped treatment
Proportion of patients with at least one grade 3/4 adverse event
Proportion of patients with at least one grade 3/4 adverse event
Proportion of patients with at least one severe adverse event
Proportion of patients with at least one severe adverse event
Proportion of patients who were non-adherent to drugs
Proportion of patients who were non-adherent to drugs (<90% pill count or <90% of self-reported drug intake)
Reasons for non-adherence assessed by pill count (descriptive analysis)
Reasons for non-adherence assessed by pill count (descriptive analysis)
Cost-effectiveness of the 3 treatment algorithms
Cost-effectiveness of the 3 treatment algorithms
Proportion of patients with white coat hypertension, as determined by 24h ambulatory blood pressure measurement
Proportion of patients with white coat hypertension, as determined by 24h ambulatory blood pressure measurement
Proportion of patients with blood pressure control determined by 24h ambulatory blood pressure measurement (24h mean blood pressure <130/80mmHg irrespective of age)
Proportion of patients with blood pressure control determined by 24h ambulatory blood pressure measurement (24h mean blood pressure <130/80mmHg irrespective of age)
Reasons for non-adherence assessed by self-report (descriptive analysis)
Reasons for non-adherence assessed by self-report (descriptive analysis)

Full Information

First Posted
October 3, 2019
Last Updated
October 19, 2022
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Swiss National Fund for Scientific Research
search

1. Study Identification

Unique Protocol Identification Number
NCT04129840
Brief Title
Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa
Acronym
coArtHA
Official Title
Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa - A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
March 5, 2020 (Actual)
Primary Completion Date
September 22, 2022 (Actual)
Study Completion Date
September 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
Swiss National Fund for Scientific Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is to compare the effectiveness of three different antihypertensive treatment strategies for reaching a target blood pressure (clinic BP) of </= 130/80 mmHg among patients <65years of age and </= 140/90 mmHg among patients >/=65years of Age in HIV-positive and HIV-negative patients with uncomplicated arterial hypertension in rural Tanzania and Lesotho.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Hypertension
Keywords
antihypertensive treatment

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The intervention is a treatment algorithm (comparing two combination treatment strategies with the World Health Organization (WHO) standard and not an individual drug.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1268 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention 1: dual combination
Arm Type
Active Comparator
Arm Description
dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
Arm Title
Intervention 2: triple combination
Arm Type
Active Comparator
Arm Description
triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
Arm Title
Standard of care
Arm Type
Placebo Comparator
Arm Description
start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point
Intervention Type
Other
Intervention Name(s)
dual combination
Intervention Description
Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
Intervention Type
Other
Intervention Name(s)
triple combination
Intervention Description
Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
Intervention Type
Other
Intervention Name(s)
Standard of care
Intervention Description
Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
Primary Outcome Measure Information:
Title
Proportion of patients reaching a target blood pressure
Description
Proportion of patients reaching a target blood pressure (clinic blood pressure) of </=130/80 mmHg in patients <65years of age and </=140/90 mmHg in patients >65years of age
Time Frame
at 12 weeks after enrolment
Secondary Outcome Measure Information:
Title
Proportion of patients reaching a target blood pressure
Description
Proportion of patients reaching a target blood pressure (clinic blood pressure) of </=130/80mmHg in patients <65years of age and </=140/90mmHg in patients >65years of age
Time Frame
at 4, 8 and 24 weeks after enrolment
Title
Change in blood pressure (mmHg)
Description
Change in blood pressure (change from enrolment) (mmHg)
Time Frame
at 4, 8, 12, 24 weeks after enrolment
Title
Proportion of patients with treatment adaptations made to the primary treatment
Description
Proportion of patients with treatment adaptations made to the primary treatment (dose increases and/or drug additions)
Time Frame
within 12 weeks after enrolment
Title
Number of treatment adaptations per patient made to the primary treatment
Description
Number of treatment adaptations per patient made to the primary treatment
Time Frame
within 12 weeks after enrolment
Title
Time until first target blood pressure of </=130/80 mmHg in patients <65years of age and </=140/90mmHg in patients >65years of age
Description
Time until first target blood pressure of </=130/80 mmHg in patients <65years of age and </=140/90mmHg in patients >65years of age
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients with major cardiovascular endpoints
Description
Proportion of patients with major cardiovascular endpoints such as death, stroke, myocardial infarction, heart failure)
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients with changes in surrogate markers for hypertension-mediated organ damage
Description
Proportion of patients with changes in surrogate markers for hypertension-mediated organ damage (resolving, newly occurring or worsening)
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients lost to follow up or stopped treatment
Description
Proportion of patients lost to follow up or stopped treatment
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients with at least one grade 3/4 adverse event
Description
Proportion of patients with at least one grade 3/4 adverse event
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients with at least one severe adverse event
Description
Proportion of patients with at least one severe adverse event
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients who were non-adherent to drugs
Description
Proportion of patients who were non-adherent to drugs (<90% pill count or <90% of self-reported drug intake)
Time Frame
at 12 weeks after enrolment
Title
Reasons for non-adherence assessed by pill count (descriptive analysis)
Description
Reasons for non-adherence assessed by pill count (descriptive analysis)
Time Frame
within 24 weeks after enrolment
Title
Cost-effectiveness of the 3 treatment algorithms
Description
Cost-effectiveness of the 3 treatment algorithms
Time Frame
within 24 weeks after enrolment
Title
Proportion of patients with white coat hypertension, as determined by 24h ambulatory blood pressure measurement
Description
Proportion of patients with white coat hypertension, as determined by 24h ambulatory blood pressure measurement
Time Frame
within 12 weeks after enrolment
Title
Proportion of patients with blood pressure control determined by 24h ambulatory blood pressure measurement (24h mean blood pressure <130/80mmHg irrespective of age)
Description
Proportion of patients with blood pressure control determined by 24h ambulatory blood pressure measurement (24h mean blood pressure <130/80mmHg irrespective of age)
Time Frame
within 12 weeks after enrolment
Title
Reasons for non-adherence assessed by self-report (descriptive analysis)
Description
Reasons for non-adherence assessed by self-report (descriptive analysis)
Time Frame
within 24 weeks after enrolment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV-positive and negative patients of African descent and black ethnicity with a documented uncomplicated, untreated arterial hypertension (blood pressure >/=140/90 mmHg) diagnosed at one of the 2 study sites Exclusion Criteria: Current hospitalization for any reason Not of African descent Refusal of an HIV-test or indeterminate HIV test result History of cardiovascular event in the last month (anginal pain, stroke, myocardial infarction or diagnosis by a doctor) Symptomatic arterial hypertension (blood pressure >/=180/110 mmHg plus headache or chest pain) or acute cardiovascular event acute disease, (e.g. fever >37.5°C or other signs of acute concomitant infection; Dyspnea/respiratory distress; Acute pain) Clinical signs of hypertension-mediated organ damage (heart failure, bilateral pitting edema, bilateral crackles or pleural effusion, distended jugular veins, ischemic heart disease (anginal pain on exertion), signs of current ischemic/hemorrhagic stroke (hemiparesis, loss of consciousness) Pregnancy (test required for females 18-45years of age) Non-consenting or inability to come for follow-up visits creatinine clearance </=30ml/min by Chronic Kidney Disease Epidemiology Formula (CK-EPI) estimation and measurement with a point-of care creatinine from capillary blood
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maja Weisser Rohacek, PD Dr.
Organizational Affiliation
Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel
Official's Role
Principal Investigator
Facility Information:
Facility Name
SolidarMed Lesotho, Mokhotlong Government Hospital
City
Mokhotlong
Country
Lesotho
Facility Name
Division of Infectious Diseases & Hospital Epidemiology; University Hospital Basel
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
St. Francis Referral Hospital/ Ifakara Health Institute
City
Ifakara
State/Province
Morogoro
Country
Tanzania

12. IPD Sharing Statement

Citations:
PubMed Identifier
33478567
Citation
Mapesi H, Gupta R, Wilson HI, Lukau B, Amstutz A, Lyimo A, Muhairwe J, Senkoro E, Byakuzana T, Mphunyane M, Bresser M, Glass TR, Lambiris M, Fink G, Gingo W, Battegay M, Paris DH, Rohacek M, Vanobberghen F, Labhardt ND, Burkard T, Weisser M. The coArtHA trial-identifying the most effective treatment strategies to control arterial hypertension in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials. 2021 Jan 21;22(1):77. doi: 10.1186/s13063-021-05023-z.
Results Reference
derived

Learn more about this trial

Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa

We'll reach out to this number within 24 hrs